Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ibrexafungerp · Brexafemme, SCY-078

Small molecule · Inhibitor of beta-1,3-D-glucan synthase · developed by Glaxosmithkline

Approved FDA, Jun 2021
5 Registered trials

What is Ibrexafungerp?

Ibrexafungerp is a triterpenoid antifungal, a semisynthetic derivative of enfumafungin, that inhibits beta-1,3-D-glucan synthase, an enzyme needed for fungal cell wall synthesis. It is studied in invasive candidiasis, aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and other fungal infections.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Brexafemme, SCY-078, MK-3118
Drug type
Small molecule
Targets
beta-1,3-D-glucan synthase
Mechanism
Inhibitor of beta-1,3-D-glucan synthase
Pathways
fungal cell wall synthesis
Therapy area
Infectious disease
Developer
Glaxosmithkline
In trials of
SCYX
FDA status
Approved as Brexafemme (June 1, 2021), NDA214900 · FDA label
UNII
A92JFM5XNU

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 7, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05178862 Phase 3 Candidiasis, Invasive Terminated SCYX
NCT03059992 Phase 3 Invasive Candidiasis Completed SCYX
NCT04307082 Phase 1 Fungal Infection Completed SCYX
NCT04092751 Phase 1 Pharmacokinetics Completed SCYX
NCT04092725 Phase 1 Pharmacokinetics Completed SCYX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Allergic Bronchopulmonary AspergillosisBlastomycosisCandidemiaCandidiasis, InvasiveChronic Pulmonary AspergillosisCoccidioidomycosisFungal InfectionHistoplasmosisInvasive CandidiasisInvasive Pulmonary AspergillosisMucocutaneous CandidiasisOther Emerging FungiPharmacokineticsRecurrent Vulvovaginal Candidiasis

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.